Caplin Point gets approval for sterile injectables from Colombia

Caplin Point today informed the bourses that it has received Colombia's INVIMA approval for its small volume sterile injectable division at Puducherry.

The site inspection of the company’s Unit 1 was completed on May 10. The company has been found compliant as per INVIMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).

The company is hoping that this approval would help to further expand its footprints in Latin America. The company’s Unit 1 is currently catering to emerging markets of Latin America and Africa with a variety of dosage forms such as tablets, capsules, softgel capsules, suppositories, liquid orals and topicals.

Caplin Point Laboratories is majorly engaged in the manufacturing of a wide range of ointments, creams and other external application preparations in addition to the regular segments of pharmaceutical formulations.

On Monday, the stock of Caplin Point Laboratories opened at Rs. 333.05 and made an intra-day high of Rs 335.25 and finally closed at Rs. 330 on the BSE. The stock had hit its 52-week high of Rs 612.90 on May 28, 2018 and 52-week low of Rs. 304.75 on January 29, 2019 on the BSE.